Price movement over the last 24 hours
AdaptHealth Corp vs Macy's Inc — how do they compare? AdaptHealth Corp trades at $10.02 (market cap $1.38B), while Macy's Inc trades at $22.53 (market cap $6.08B). The key difference: Macy's Inc is far larger — about 4.4× AdaptHealth Corp's market cap, and Macy's Inc pays a 3.31% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | M | |
|---|---|---|
Market Cap | $1.38B | $6.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $13.38 | $25.96 |
52-Week Low | $8.68 | $11.90 |
Enterprise Value | $3.33B | $9.90B |
Dividend Yield | — | 3.31% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Macy's (M) trades at $23.13, down 0.52% on the day, with technical indicators showing a bullish trend supported by moving averages. The stock shows attractive valuation metrics with a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. The company's 'Bold New Chapter' strategy is gaining traction with improved comparable sales and digital growth, supported by Berkshire Hathaway's new 3.04 million-share position disclosed in Q1 2026.
Macy's presents a compelling value opportunity with strong institutional interest and operational improvements, though investors face risks from retail sector headwinds and margin pressure. The consensus price target of $23.80 suggests modest upside potential, while execution on turnaround initiatives remains critical for sustained growth.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →